BofA analyst Tazeen Ahmad raised the firm’s price target on Incyte (INCY) to $87 from $86 and keeps a Buy rating on the shares. The firm ...

Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Incyte (INCY – Research Report) today and set a price target of ...

Valued at a market cap of $11.5 billion, Incyte Corporation (INCY) is a biopharmaceutical company that discovers, develops, ...

Shares of Incyte Corp. rallied 4.13% to $59.22 Monday, on what proved to be an all-around favorable trading session for the ...

Founded in 1991 and evolving from a genomics research firm to a commercial-stage drug developer, Incyte (NASDAQ:INCY) is a biopharmaceutical company that discovers, develops, and commercializes ...

Incyte Corp. closed 32.26% below its 52-week high of $83.95, which the company achieved on November 8th.

The US Court of Appeals for the Federal Circuit vacated a preliminary injunction on Leqselvi’s launch, lifting restrictions on the launch on April 9, Sun Pharma said in a regulatory filing.

According to market estimates, Leqselvi is projected to contribute $90 million to Sun Pharma's sales in FY26, and $125 ...

Emkay Global Financial Services, in a client note, described the development as “materially positive,” as it removes a key ...

Emkay Global maintains a 'Buy' rating on Sun Pharma after the US Court of Appeals vacates the injunction against Leqselvi's ...

Sun Pharma shares gained after a U.S. court lifted an injunction, clearing the way for the launch of LEQSELVI, its drug for ...

Incyte Corp. closed 34.28% below its 52-week high of $83.95, which the company achieved on November 8th.